although far advanced hepatocellular carcinoma (Hcc) is generally considered a contraindication for liver transplantation (lt), biologically favorable tumors among them could show acceptable results. However, it is still unclear which tumors can be treated with lt. Data were collected on adult patients who underwent lt for Hcc beyond the Milan criteria in 8 Korean lt centers between January 2000 and June 2013. Far advanced Hcc was defined as Hcc with the largest tumor ≥ 10 cm, 10 or more tumor nodules, or accompanying macrovascular invasion. a total of 688 patients, including 169 with far advanced Hcc, were enrolled in this study. the 5-year overall and recurrence-free survival rates were 60.4% and 55.1%, respectively, for all patients but only 28.7% and 24.8%, respectively, for patients with far advanced Hcc (P < 0.001). Both preoperative alpha-fetoprotein (aFP) and protein induced by vitamin K absence or antagonist ii (PiVKa-ii) were significant risk factors for Hcc recurrence after lt. in particular, aFP + PiVKa-ii combined was a better predictor than either marker alone. Of all far advanced Hcc patients with available aFP and PiVKa-ii levels, 45 (30.8%) had low aFP + PiVKa-ii (≤300) and their 5-year overall and recurrence-free survival rates were 47.8% and 53.4%, respectively, which were acceptable and significantly superior to those of patients with aFP (ng/ml) + PiVKa-ii (naU/ml) > 300 (21.0% and 10.8%, respectively; P < 0.001). in conclusion, patients with favorable Hcc had acceptable outcomes after lt even when their tumors were extremely advanced. aFP + PiVKa-ii gave reliable information about the tumor biology of far advanced Hcc. Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea. Telephone: +82-2-2072-3789; FAX: +82-2-766-3975; E-mail: kssuh@snu.ac.kr Liver transplantation (LT) has been considered 1 of the best treatment options for early hepatocellular carcinoma (HCC) since the Milan criteria (MC) were suggested by Mazzaferro et al. in 1996 . The MC are defined as a single tumor with a maximum size of 5 cm or 3 or fewer tumors with the largest not exceeding 3 cm and no major vascular invasion or extrahepatic spread. (1) In their first study, they found that their patients with HCCs that met the MC had a 75% overall survival rate and an 83% recurrence-free survival rate 4 years after LT.
Liver transplantation (LT) has been considered 1 of the best treatment options for early hepatocellular carcinoma (HCC) since the Milan criteria (MC) were suggested by Mazzaferro et al. in 1996 . The MC are defined as a single tumor with a maximum size of 5 cm or 3 or fewer tumors with the largest not exceeding 3 cm and no major vascular invasion or extrahepatic spread. (1) In their first study, they found that their patients with HCCs that met the MC had a 75% overall survival rate and an 83% recurrence-free survival rate 4 years after LT. (1) The MC justified LT for HCC by improving the longterm results to levels comparable with those of LT for nonmalignant diseases. (2) Thus, the MC is undoubtedly the standard of choice for patient selection for LT for HCC. Nonetheless, various new expanded criteria for LT for HCC have been continuously proposed from transplant centers worldwide even in the post-MC era. (2) The University of California, San Francisco criteria and up-to-7 criteria are well-known representatives. (3, 4) All attempts to further expand the criteria for LT for HCC are based on the thinking that the MC might be too restrictive and thus prevent some patients from benefiting from LT. (5) (6) (7) (8) Nonetheless, with deceased donor liver transplantation (DDLT), expanding LT for HCC should be tempered because the excessive criteria expansion could limit the access to LT of patients with other liver diseases and impair the overall outcomes after LT. (9) Living donor liver grafts, however, are not public resources and thus not allocated by the public organ sharing system. (10, 11) Therefore, living donor liver transplantation (LDLT) for advanced HCC is a treatment option if the outcomes are acceptable, although a lower survival rate is expected compared with that for DDLT. (8, 12) In Korea, LDLT still accounts for more than 70% of all LT cases despite a rapidly increasing rate of DDLT. (13) Hence, Korean LT centers have much more experience with LT for advanced HCC than any other countries.
Although several expanded criteria for LT for HCC has been proposed for both LDLT and DDLT, it is still unclear how far we can go for LT for advanced HCC. (8) Moreover, the results of LT for far advanced HCC exceeding general expanded criteria are not well-known, and risk factors for post-LT recurrence of these HCCs have also not been clarified. The size and number of tumors are conventional markers that have been used in most selection criteria; they are clear indicators to predict HCC recurrence after LT. However, they alone are not sufficiently effective for selecting favorable tumors that are not aggressively disseminated after LT. (12) Recently, the significance and utility of biomarkers such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II) have been suggested in predicting posttransplant recurrence. (14) Even far advanced HCC in terms of size and number might show satisfactory outcomes after LT if biological markers are acceptably low. (15) These markers could be effectively used to decide whether a HCC is suitable for LT or not, especially when tumors are morphologically advanced. Therefore, the purpose of this study was to investigate the outcomes of LT for extremely advanced HCC based on Korean experiences and to establish a new selection strategy using AFP and PIVKA-II for patients with these tumors.
Patients and Methods

patIentS
For this study, we retrospectively collected the medical data of patients who underwent LT for advanced HCC beyond the MC between January 2000 and June 2013 from 8 LT centers in Korea: Seoul National University Hospital, Seoul National University Bundang Hospital, Seoul National University Boramae Medical Center, Asan Medical Center, Samsung Medical Center, National Cancer Center Korea, Yonsei University Severance Hospital, and Korea University Anam Hospital. We only enrolled adult patients in the study, whose age was 18 years or older at the time of LT. This study had been approved by the institutional review board of each center participating in this study before the data collection.
All patient data were collected via mail or e-mail without private information. A case report form was developed before institutional review board evaluation and the multicenter survey. Institution staffs were asked to complete 1 case report form per patient, with data including demographic characteristics, date and type of transplantation, underlying liver disease, HCC status on pretransplant imaging, the last AFP and PIVKA-II levels before LT, pathologic reporting on the explant liver, and HCC recurrence and survival or death.
HCC MeaSUreMent
The diagnosis and measurement of HCC was based on the pathologic reports to minimize the disparity among transplant centers and to improve the accuracy. Only patients with pathologically proven HCC beyond the MC were enrolled in this study. Patients with tumors that fulfilled the MC on the explant liver were excluded even though they were preoperatively suspicious for exceeding the MC. In addition, totally necrotic nodules were not counted regardless of pretransplant treatments, and thus, patients with HCC Original article | 1245 downstaged into the MC after bridge treatments were also excluded. The size of tumors was defined as the diameter of the largest tumor based on the pathologic report. The size ≥ 10 cm was considered as 10 cm. The number of tumors ≥ 10 was considered as 10. Macrovascular invasion was characterized by tumor thrombus pathologically confirmed in a sectional or larger portal vein or the main hepatic vein. Definite tumor thrombi on preoperative imaging that were enhancing or outgrowing from tumors were also considered macrovascular invasion.
We regrouped patients into an advanced group and a far advanced group. Far advanced HCC was defined as HCC with maximum size or number of tumors, or macrovascular invasion. Thus, patients with HCC ≥10 cm, 10 or more tumor nodules, or accompanying macrovascular invasion were included in the far advanced group and the others were included in the advanced group.
Data anaLYSIS
Posttransplant overall and recurrence-free survival curves were statistically generated by the KaplanMeier method and compared by the log-rank test. The risk factors for HCC recurrence were investigated with a Cox regression model, and a receiver operating characteristic (ROC) curve was used to evaluate the efficacy of serum AFP and PIVKA-II levels as predictors of HCC recurrence. All statistics analyses were performed using IBM SPSS Statistics, version 20 analysis software (IBM, Armonk, NY).
results
aDvanCeD anD Far aDvanCeD GroUp
Among those who underwent LT at 8 Korean LT centers between January 2010 and June 2013, a total of 688 patients had pathologically proven HCC beyond the MC. There were 612 (89.0%) patients who were male, and the others (11.0%) were female. The mean age of patients at the time of transplantation was 53.8 ± 7.7 years. The most common underlying liver disease was hepatitis B virus (HBV)-related liver disease (86.8%). The mean Child-Turcotte-Pugh score and Model for End-Stage Liver Disease (MELD) score were 8.0 ± 2.4 and 14.1 ± 7.3, respectively. About three-quarters of patients had HCC treatment history before transplantation. Most patients underwent LT from a living donor (Table 1) . Median follow-up duration was 2.9 years after LT (range, 0.0-14.5 years). The overall survival rates of whole patients were 60.4% at 5 years and 51.8% at 10 years. The recurrence-free survival rates were 55.1% at 5 years and 49.6% at 10 years.
Following our definition in the present study, 169 (24.6%) patients underwent LT for far advanced HCC. Of these, 24 (14.2%) had a tumor with a maximum diameter of 10 cm or more, and 73 (43.2%) patients had 10 or more tumor nodules. Furthermore, 99 (58.6%) patients had macrovascular invasion. Excluding them, 519 patients were included in the advanced group. The 5-year overall and recurrence-free survival rates of the far advanced group were 28.7% and 24.8%, respectively, which were significantly inferior to the rates of the advanced group (70.4% and 64.9%, respectively; both P < 0.001; Fig. 1 ).
aFp anD pIvKa-II
In univariate analysis, size of tumors, number of tumors, macrovascular invasion, microvascular invasion, and pretransplant serum AFP and PIVKA-II were risk factors for HCC recurrence after LT. In the multivariate analysis, size of tumors, number of tumors, and macrovascular/microvascular invasion were still significant factors (Table 2 ). AFP and PIVKA-II were not independent risk factors in the multivariate analysis. However, because we assumed that these tumor markers would be effective to predict posttransplant recurrence for HCCs with extreme size/number or macrovascular invasion, we focused on pretransplant AFP and PIVKA-II levels. We did not consider microvascular invasion because it cannot be reliably identified before transplantation even after an invasive biopsy procedure. (8, 16) The ROC curves showed that both AFP and PIVKA-II were fairly correlated with HCC recurrence after LT. The area under the curve (AUC) for both were 0.667 and 0.666, respectively. In addition, the sum of the 2 tumor markers increased the predictive power. The AUC for AFP (ng/mL) + PIVKA-II (nAU/mL) level was 0.708 in the whole study group and 0.809 in the far advanced group (Fig. 2) . The estimated ideal cutoff value of AFP + PIVKA-II for prediction of recurrence was 288.7 in the far advanced group.
tUMor MarKerS anD HCC reCUrrenCe
We considered 300 as the cutoff of AFP + PIVKA-II for prediction of HCC recurrence, which was simplified from the ideal value, 288.7. On the basis of this cutoff, patients were restratified into 2 groups: a lowrisk group (AFP + PIVKA-II ≤ 300) and a high-risk group (AFP + PIVKA-II > 300 Original article | 1247
respectively. The actuarial 5-year overall and recurrence-free survival rates of the low-risk far advanced group was calculated to be 47.8% and 53.4%, respectively, which were significantly superior to those of the high-risk far advanced group (21.0% and 10.8%, respectively; P < 0.001; Fig. 3 ). In particular, the survival rates of the low-risk far advanced group were comparable to those of the high-risk advanced group (P = 0.86 for overall survival; P = 0.27 for recurrencefree survival).
We also performed a subgroup analysis according to far advanced factors. The 5-year overall and recurrence-free survival rates were 29.8% and 25.4% for 99 patients with macrovascular invasion and 24.6% and 19.1% for 77 patients with 10 or more tumors, respectively. In addition, the 3-year overall and recurrence-free survival rates for 24 patients with tumor size ≥10 cm were 19.0% and 15.0%. We found significant survival differences between the low-risk and high-risk groups also in subgroup analyses (Fig. 4) . However, presence of macrovascular invasion had no effect on recurrence-free survival in the far advanced group (Fig. 4) .
Discussion
In DDLT, the donor livers, which are public resources, should be first allocated to candidates with longterm expected survival in light of the serious organ shortage; a too-liberal expansion of the selection criteria for LT for HCC is not advised. Hence, most expanded criteria that have been suggested for DDLT showed longterm survival rates of >70%, not significantly inferior to those under the MC. (8) However, LDLT differs from DDLT in that because LDLT is performed based on private relationships between the donor and the recipient, liver grafts are dedicated to only 1 potential recipient. (2, 8) Expanding the LDLT criteria for HCC would not result in decreased LT opportunities for patients with other etiologies, and thus, slightly lower expected survival could be acceptable in LDLT. (15, 17) In fact, most Asian LDLT centers adopt more aggressive criteria than do their Western counterparts. (17) They make final decisions on a case-bycase basis, comprehensively considering the overall survival chance of the recipient and the wishes of the donor as well as the risk of recurrence after LT. (8, 17) Nonetheless, the minimal acceptable survival rate for LDLT is still controversial because LDLT is inevitably accompanied by significant risks of morbidity and mortality for the healthy donors. (8) The risks of death and life-threatening complications for living donors have been reported to be 0.3% and 2.0%, respectively. (18) (19) (20) Fortunately, in high-volume LDLT centers, the major complication rates for living donors can be reduced by increased skill including surgical experience and established donor selection policies. (11) However, many patients with advanced HCC have   FIG. 3 . Survival rates after transplantation by tumor markers: (A) overall survival and (B) recurrence-free survival. Of all patients in the far advanced group, 30% were classified into the low-risk group (AFP + PIVKA-II ≤ 300), and they had acceptable 5-year overall and recurrence-free survival rates after LT (47.8% and 53.4%, respectively) that were comparable to those of the highrisk advanced group (P = 0.86 for overall survival; P = 0.27 for recurrence-free survival).
few better treatment options than LT, and for these patients, LDLT could be the only chance to save their lives. Choosing LDLT depends heavily on the balance between recipient benefit and donor risk. (12) Hence, if a recipient could clearly benefit from LT with a similar donor risk, much lower expected survival might be considered acceptable for LDLT. Here, we suggest that the target survival rate should be adjusted down to approximately 50% for LDLT for far advanced HCC if a patient has no better treatment options than LT and a well-informed donor strongly wishes to provide the only chance of a cure to the patient.
In the present study, patients with far advanced HCCs accounted for about a quarter of patients whose tumors exceeded the MC. Their 5-year recurrence-free survival rate was only 24.8%, much lower than that for the others. However, some tumors may have favorable tumor biology even if they are morphologically far advanced. Among known tumor markers, AFP and PIVKA-II are most widely used in the clinical field. (14, (21) (22) (23) (24) (25) Thus, we used them to predict tumor recurrence risk after LT. In addition, because their clinical priority was differently assessed in previous studies, we expected that they might complement each other. Finally, the ROC curve 
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showed that serum AFP + PIVKA-II was a better predictor of posttransplant recurrence for advanced HCC than was either marker alone. Patients with AFP + PIVKA-II < 300 showed a recurrence-free survival rate of 53.4% even if they had far advanced HCC before LT. Moreover, they comprised 30% of patients with far advanced HCC. Conventional selection criteria would have excluded these patients from LT candidacy, and even most Asian expanded criteria that use tumor markers for candidate selection have an upper limit on tumor size and number. (8) However, the present study showed that if tumor biology is favorable regardless of tumor size and number, acceptable longterm survival after LT can be expected. In addition, although HCC with macrovascular invasion is considered an absolute contraindication for LT in nearly all selection criteria worldwide, these tumors also showed acceptable outcomes when their tumor marker levels were low. Moreover, in patients with far advanced HCC, presence of macrovascular invasion was not a significant risk factor for HCC recurrence. It was not as effective as tumor markers to predict recurrence after LT for far advanced HCC. Therefore, according to our study results, a number of patients with far advanced HCC can have a chance of life based on our tumor markerbased patient selection.
The significance of tumor biological markers for selecting HCC patients for LT has been increasingly reported. (14) Although several inflammatory markers including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein were recently proposed, (26) (27) (28) the markers that have been the most studied are AFP, PIVKA-II, and positron emission tomography (PET). Among them, AFP and PIVKA-II have been already adopted and used for patient selection in several transplant centers. (25, (29) (30) (31) However, most centers use only 1 of the 2 in their selection criteria, and the suggested cutoff levels for AFP and PIVKA-II differ greatly based on individual institutional experiences. Two recent studies suggested the combination of both tumor markers, similar to the present study. (32, 33) Chaiteerakij et al. (32) proposed risk factor combination of AFP ≥ 250 ng/mL and des-gamma-carboxyprothrombin ≥ 7.5 ng/ mL. This combination was more effective to predict HCC recurrence than was either marker alone, which was similar to the present study. They suggested that both tumor markers should be used together with the MC to decide LT eligibility. Lee et al. (33) calculated their risk scores for HCC beyond MC as 11 × √PIVKA-II +2 × √AFP based on Cox proportional hazards model and recommended the score of 314.8, which was at the 75th percentile for recurrence as the ideal cutoff value. The authors did not use the tumors' morphological factors for their scoring system because the size and number of tumors were not independently significant risk factors for post-LT recurrence based on multivariate analysis, whereas √AFP and √PIVKA-II were significant. (33) In our study based on pathologic examination, we found that tumor size and number were not exactly measured for advanced HCC by pretransplant imaging, but they were still independent risk factors for HCC recurrence even beyond the MC. Thus, the scoring system discussed above that excluded tumor size and number needs to be prospectively validated. Unlike with the above study, the aim of the present study was to establish a selection strategy for LT for far advanced HCC with maximum tumor size and number or macrovascular invasion. The AFP + PIVKA-II level that we propose here could thus be effective for selecting patients who could benefit from LT despite far advanced HCC. PET is also a significant biological marker, but unfortunately, we could not consider PET results in the present analysis because of the diagnostic ambiguity. PET positivity depends on nuclear radiologists, and although some studies suggested useful definitions of PET positivity for HCC, (34) it was difficult to apply those definitions to the present retrospective multicenter study. Nonetheless, PET is still an important biomarker that should be further studied.
So far, few studies have reported LT results for far advanced HCC. With DDLT, LT is highly unlikely for patients with HCCs that greatly exceed the MC. This study might be the first to report reliable LT results for far advanced HCC. We enrolled a total of 169 patients in this study by means of multi-LDLT center cowork, and in our results, even patients with seriously advanced HCC had significant benefits from LT if their tumors were biologically favorable. Serum AFP + PIVKA-II was a reliable indicator of favorable tumors for LDLT. However, our study was based on the pathological data from explanted livers for accurate tumor diagnosis and measurement among centers. In actual clinical settings, tumors are preoperatively assessed by imaging modalities, which could underestimate or overestimate tumor status. Hence, the results should be validated based on the preoperative imaging. In addition, the expected survival of 50% may not be acceptable for DDLT. Therefore, although we included DDLT cases in the present analysis, the derived AFP + PIVKA-II cutoff for far advanced HCC may be applicable only to LDLT cases. Moreover, we did not in the present study emphasize that LDLT should be recommended for all patients with far advanced HCC and low tumor markers; we only discussed the upper limit we can consider for LDLT for patients with far advanced HCC. Before transplantation for these patients, clinicians should thoroughly inform both patients and donors about not only the high risk of HCC recurrence but also the subsequent potentially poor outcomes.
In conclusion, LT for far advanced HCCs that greatly exceed the MC showed very poor outcomes and thereby should not be generally recommended. However, in LDLT, when a liver graft is dedicated to only 1 potential recipient, even patients with those advanced tumors can be selectively considered candidates for LT. Of all patients with far advanced HCC, approximately 30% had preoperative AFP + PIVKA-II ≤ 300, and they showed good 5-year overall and recurrence-free survival rates of near 50% after LT. Therefore, tumors with favorable biology, despite having extremely advanced morphology, can be treated by LDLT with considerably positive expectations, and the AFP + PIVKA-II level could give reliable information for these cases.
